Skip to content
Previous Next

"The acquisition brings to HRA Pharma one of the European’s premier consumer brand in blister care and lip care treatment," said David Wright, Chief Executive Officer of HRA Pharma. “This transaction doubles our revenue streams and expands our markets while supporting the company’s strategy of becoming one of the fastest growing global Consumer Healthcare companies, empowering people throughout the world to improve their lives by developing accessible, value added self-care solutions.”

With the acquisition, the HRA Pharma portfolio will now encompass four well-known consumer and OTC brands in blister care, lip care, emergency contraception and intimate care. In the years to come, HRA Pharma intends to pursue its development combining organic growth with targeted acquisitions, based on three strategic priorities: international expansion, strategic brands pipeline development, and increasing presence in consumer healthcare sector.

Debt for the acquisition was provided by Goldman Sachs, Nomura and HSBC. Advisors involved for HRA Pharma included: Rothschild (financial advisor), BCG (strategic due diligence), PWC (financial due diligence), Dechert (legal advisor), Freshfields (sponsors’ legal advisor, financing), Ashurst (lenders’ legal advisor).

About HRA Pharma

HRA Pharma is a fast growing, innovative consumer healthcare company, empowering people throughout the world to improve their lives by developing accessible, value added, self-care solutions. Historically centered on women’s health, the company has become the European leader in emergency contraception. With ambitious projects in the pipeline, including innovative Rx-to-OTC switches, HRA Pharma is committed to bringing a range of innovative products and services to market, particularly in areas of unmet customer needs. Headquartered in Paris, France with subsidiaries across Western Europe and a global network of local partners covering over 90 countries, the company has a proven structure, the skills and experience to capture new consumer healthcare businesses and deliver high quality brands on a global scale. In 2016, the Company’s full-year revenue increased 15 percent to € 102 million. Visit www.hra-pharma.com for more information.

Further information

Latest news